Background: Patients with coronary heart disease (CHD) require long-term therapy with low-dose aspirin (ASA). Although these patients are at increased risk for upper gastrointestinal bleeding (UGIB) and proton pump inhibitor (PPI) cotherapy may reduce such risk, it is not known whether lifelong PPI cotherapy is cost-effective.
C
URRENT GUIDELINES RECommend that patients with established coronary heart disease (CHD) use low-dose (75-325 mg) aspirin (ASA) indefinitely for prevention of recurrent cardiovascular (CV) events. 1, 2 Although the CV benefits of ASA are widely accepted, ASA also carries a small but clinically important risk of upper gastrointestinal bleeding (UGIB) (0.25% -1% per patient-year). 3 Also, UGIB carries significant risk of morbidity and mortality, particularly in patients with CHD. [4] [5] [6] Furthermore, low-dose ASA is the most common cause of GI bleeding-related mortality, accounting for one-third of bleeding-related deaths nationally in a recent Spanish study. 7 One approach that can reduce the risk of UGIB in patients taking low-dose ASA is cotherapy with a proton pump inhibi-tor (PPI); PPIs have been shown to reduce the risk of bleeding in 2 randomized controlled trials. 8, 9 Although these trials enrolled patients at high risk for ulcer bleeding (ie, those with a history of peptic ulcer disease), observational studies 10-12 support a similar benefit for patients at average risk of bleeding. Despite these data supporting the effectiveness of PPI cotherapy, the question of whether such cotherapy is cost-effective remains unanswered. Although prior models have explored the role of PPI cotherapy in users of traditional-dosage, nonsteroidal antiinflammatory drugs (NSAIDs), [13] [14] [15] [16] lowdose ASA carries a markedly lower risk of bleeding, and the role of PPI cotherapy in users of low-dose ASA alone has not been explicitly studied. The recent availability of low-cost over-the-counter (OTC) PPIs has also not been studied. The purpose of this study was to model the clinical and economic effects of PPI cotherapy in patients taking long-term, low-dose ASA for secondary prevention of cardiovascular events, from the perspective of a longterm payer such as Medicare. We explic-itly compared the cost-effectiveness of low-cost OTC PPIs, such as omeprazole magnesium, to that of higher-cost prescription (Rx) PPIs, such as esomeprazole magnesium, rabeprazole sodium, and pantoprazole sodium. We employed an age-dependent risk of UGIB and UGIBrelated mortality and also studied the impact of additional risk factors for UGIB. With this approach, we defined patient subgroups for which PPI cotherapy is cost-effective and identified additional areas of research for defining a rational approach to reducing the risk of low-dose ASA therapy.
METHODS

DECISION ANALYTIC MODEL
We developed a Markov cohort model using TreeAge Pro decision modeling software (TreeAge Software Inc, Williamstown, Massachusetts). Two competing strategies were mod-eled: (1) an ASA-alone strategy, in which the cohort was started on treatment with ASA alone, and gastroprotection (ASA plus PPI) was used only if a UGIB event occurred; and (2) an ASA plus PPI strategy, in which the cohort was started on treatment with ASA plus PPI and switched to clopidogrel bisulfate plus PPI in the event of UGIB. The base-case cohort was composed of a 65-year-old, adherent, ASA-tolerant population with no additional risk factors for UGIB using ASA for secondary prevention of CV events. The simulation began with the entire cohort using ASA (hereinafter, ASA state) with or without PPI (depending on the strategy being modeled). The cohort could then remain in the ASA state for the entire 1-year cycle or undergo a UGIB event. A bleeding event resulted in transition to a high-risk state for future UGIB events ("ASA plus PPI" or "clopidogrel plus PPI") or to a death state. 11, 17 Finally, any Markov state could transition to a death state. The basic structure of the model is outlined in Figure 1 .
UGIB RISK
The risk of UGIB in low-dose ASA users was estimated from published literature on this topic ( Table 1) . We performed a MEDLINE search for English-language systematic reviews of ASA and gastrointestinal bleeding published since 2000, using the terms aspirin, gastrointestinal, and bleeding or hemorrhage. Using this search strategy, we identified 3 recent systematic reviews 3,5,10 from which we extracted summary relative risks and crude annual risks of UGIB in low-dose ASA users. We also extracted data on independent risk factors for UGIB in users of low-dose ASA.
Commonly accepted risk factors for UGIB in patients taking low-dose ASA include age, history of UGIB, and concomitant NSAID, warfarin sodium, or corticosteroid use. Agerelated risk is unique in that it is dynamic, increasing gradually over the lifetime of the individual. We therefore modeled agerelated risk separately from other "static" risk factors (Figure 2) . 22 Furthermore, we assumed that age could be multiplicatively combined with these other risk factors. Specifically, a cohort of patients with no additional risk factors was categorized as "average risk." A cohort of patients with at least Abbreviations: B, beta distribution; CHD, coronary heart disease; N, normal distribution; OTC, over the counter; PPI, proton pump inhibitor; RR, relative risk; RRR, RR reduction; T, triangular distribution; UGIB, upper gastrointestinal bleeding. a The abbreviation in parentheses indicates the type of distribution used in probabilistic sensitivity analysis; the OTC PPI cost was varied 25% in either direction for this analysis. b The OTC PPI cost (base case) is $250, and prescription PPI cost is $1400. c The precise relationship between age and UGIB is displayed graphically in Figure 1 . d These values were selected by the authors.
1 additional risk factor was categorized as "high risk," with the precise risk increase expressed as a multiple of average risk (eg, 4 ϫ or 8 ϫ average risk). The risk of death from UGIB was also age dependent (based on data from the Rockall cohort). 23, 24 
EFFECTIVENESS OF PPI COTHERAPY
The effectiveness of PPI cotherapy in reducing UGIB risk was estimated from published literature ( Table 1) . We performed a MEDLINE search for English-language studies of ASA, PPIs, and gastrointestinal bleeding published since 1980, using the terms aspirin, gastrointestinal, bleeding or hemorrhage, and proton pump inhibitor. The generic name for each commonly used PPI was also employed in the search. Using this search strategy, we identified 2 randomized controlled trials 8, 9 of PPI cotherapy in low-dose ASA users, both of which enrolled only patients with a personal history of peptic ulcer disease. Data in average-risk patients were more limited and were observational. [10] [11] [12] Only 1 of these studies 8 explicitly used "high-dose" PPI (ie, more than once daily or at higher than the widely accepted starting dosage). Using the point estimate from the study reporting the smallest effect size, 12 we assumed that PPIs reduced bleeding risk by 66% in our base-case analysis. We then varied this effect from 25% to 75% in a sensitivity analysis based on the confidence intervals reported across these studies. 8, 9, 11, 12 A similar benefit was assumed for patients using clopidogrel. 12, 26 
CV RISK
Because CV events would be expected to occur at the same rate under both strategies (both cohorts taking an antiplatelet agent throughout the simulation), CV events were not explicitly modeled. However, the annual age-dependent probability of death was adjusted (increased in an age-dependent fashion) to account for the assumption of underlying CHD in the cohort. 21
COST INPUTS
Cost estimates used in the model included the cost of hospitalization for UGIB and the costs of the various medications studied in the model (ASA, OTC PPI, Rx PPI, and clopidogrel) ( 
OUTCOMES
Under each strategy, clinical and economic outcomes were measured and reported. Clinical outcomes included (1) UGIB events, 
SENSITIVITY ANALYSIS
Ranges for sensitivity analysis were based on published literature whenever possible. For areas in which the published literature was limited (eg, the effectiveness of PPI therapy in average-risk patients), expert opinion was also sought (A.M.F. and J.S.) and the range was widened to account for the additional uncertainty. One-way sensitivity analysis was performed on each variable in the model. Multivariate sensitivity analysis was performed on variables found to be important in 1-way sensitivity analysis. Probabilistic sensitivity analysis was also performed to assess the overall impact of uncertainty in the variables used in the model. In this analysis, 8 variables were simultaneously varied over 10 000 iterations in a cohort of average-risk, 65-year-old patients using OTC PPIs. Variable distributions for this analysis were based on the type of variable (cost, risk, or probability), point estimate, and range (Table 1) .
RESULTS
In the base-case analysis, at an OTC PPI cost of $250 per year, the ASA plus PPI strategy resulted in fewer lifetime UGIB events than ASA alone (3.1% vs 9.1% lifetime risk) and fewer UGIB-related deaths than ASA alone (0.4% vs 1.4%), with a relative risk reduction (RRR) of 67% and 71%, respectively (Figure 3 ). An ASA plus PPI was also more costly than the ASA alone (Figure 4) an ICER of approximately $40 000 per life-year saved (LYS) (cohort starting at age 65 years) ( Figure 5 and Table 2 ). These base-case results were robust to uncertainty in the input variables in probabilistic sensitivity analysis, with nearly 75% of trials remaining below a willingness-to-pay threshold of $50 000 per LYS (Figure 6 ). These results were highly sensitive to (1) the effectiveness of PPIs in reducing UGIB risk (reported as an RRR in UGIB), (2) the starting age of the cohort, (3) the UGIB risk category (average risk vs high risk), and (4) the cost of PPIs (OTC vs Rx). In an average-risk population, starting PPI therapy at a younger age was marginally cost-effective ($80 000 per LYS at age 50 years), and starting PPI therapy at an older age was highly costeffective ($17 000 at age 80 years) ( Table 2) . These results varied according to the effectiveness of PPI cotherapy in reducing UGIB risk, with assumptions of lower PPI effectiveness resulting in higher ICERs (Figure 7) . Increasing the UGIB risk of the population 3-fold or higher resulted in ICERs of less than $25 000 across all modeled age groups and assumptions of PPI effectiveness ( Figure 7 and Table 2 ).
Increasing the cost of PPIs to Rx prices markedly increased the cost of the ASA plus PPI strategy, making the strategy cost-ineffective for all but the highest-risk, oldest patients (Figure 8 and Table 2 ). At Rx prices, the ICER of the ASA plus PPI strategy for patients with a 4-fold higher risk of UGIB (compared with the average population) was $100 000 per LYS for the 50-year-old cohort, $51 000 per LYS for the 65-year-old cohort, and $25 000 for the 80-year-old cohort. At an 8-fold higherthan-average risk, the ICER remained less than $50 000 per LYS across all modeled age groups and assumptions of PPI effectiveness.
COMMENT
SUMMARY
Long-term, low-dose ASA is universally recommended in patients with a history of CHD to decrease the risk of recurrent CV events. 1, 2 Although the benefit of ASA is widely accepted, it also carries a clinically important risk of UGIB. 3 This infrequent but serious adverse effect can be minimized with PPI cotherapy. 8, 9, 11, 25 Our study demonstrates that, provided that PPIs are available at OTC prices, PPI cotherapy is a cost-effective strategy for patients older than 65 years who are taking ASA for secondary prevention and may be cost-effective for patients as young as 50 years. At Rx prices, however, cotherapy seems to be cost-effective only in high-risk patients, such as those with prior ulcer disease or those taking an additional NSAID. Our results were robust across a wide range of assumptions in sensitivity analysis and should help guide physicians in caring for their patients who are taking ASA for secondary prevention.
LITERATURE REVIEW
Despite the much lower risk of UGIB with low-dose ASA compared with higher-dose NSAIDs, the results of our study are consistent with those of prior studies [13] [14] [15] [16] that have investigated the cost-effectiveness of PPI cotherapy in patients using nonselective standard-dose NSAIDs. A study by Spiegel et al 15 compared various strategies for minimizing GI bleeding risk in patients taking NSAIDs, including PPI cotherapy. Assuming an Rx PPI cost and a static bleeding risk across age groups, the authors concluded that cotherapy was not cost-effective in patients at low risk for bleeding but was cost-effective for patients at high risk. Furthermore, PPI cost was noted to be an important factor in sensitivity analysis. Similarly, a study by Ko and Deyo 14 that also compared strategies to reduce NSAID-related GI complications found that Rx PPI cotherapy was cost-effective in patients older than 65 years but less cost-effective in younger patients. This study employed an age-related stepwise increase in UGIB-related mortality rather than a static rate across age groups. Finally, a similar study by El-Serag et al 13 found that Rx PPI cotherapy was likely to be costineffective in patients at low risk for ulcer bleeding but costeffective in patients at high risk for bleeding. This study assumed an increased risk of ulcer bleeding in patients older than 65 years. Together, these data support the notion that at Rx prices, PPI cotherapy is likely to be cost-effective only in high-risk (and older) patients, a conclusion that is consistent with the results of our study. However, our study suggests that at OTC prices, PPI cotherapy becomes increasingly cost-effective even in patients at average risk of bleeding despite the lower GI risk of low-dose ASA.
STRENGTHS AND LIMITATIONS
Several important limitations of our study should be highlighted. First, as a modeling exercise, our study is limited by the logic and assumptions of the model. How-ever, these assumptions were tested in sensitivity analysis, and the impact of important variables was further tested in multivariate sensitivity analysis. Second, we assumed a patient population that was tolerant of and adherent to the prescribed medications. By excluding the impact of PPI cotherapy on reductions in ASA-related dyspepsia, the bias in our analysis is likely to be in favor of the ASA-alone strategy. Specifically, compliance with ASA may be enhanced by a reduction in dyspepsia with PPI cotherapy. Furthermore, this reduction in dyspepsia is likely to lead to fewer physician visits and endoscopic evaluations, again favoring the ASA-alone strategy. We also assumed compliance with the PPI, which may not always occur if patients are asymptomatic. Here, competing considerations likely counterbalance and require a welldesigned trial for accurate assessment. Finally, we assumed no long-term adverse effects from PPI therapy.
Recent observational studies [28] [29] [30] have raised concerns about an increased risk of community-acquired pneumonia and hip fractures in patients taking long-term PPI therapy. Clostridium difficile and other enteric infections have also been reported, although these infections seem to primarily affect hospitalized rather than ambulatory patients. 31, 32 Whether these adverse effects are true complications of PPI therapy or spurious associations remains to be seen, but the safety of long-term PPI therapy may ultimately have important implications for the costeffectiveness of PPI-based gastroprotective strategies. Several important strengths of our study should also be mentioned. First, we utilized a continuous, agedependent risk of UGIB. Prior modeling studies used a static or step-wise risk, which may have overestimated the benefit of PPI cotherapy in younger patients and underestimated the benefit in older patients. We also specifically studied the economic effect of OTC vs Rx PPIs. Our study shows that low-cost agents have the potential to substantially improve GI outcomes for patients taking long-term, low-dose ASA for secondary prevention of CV events, at costs acceptable to society and payers as well.
In summary, PPI cotherapy is cost-effective by traditional standards in patients taking long-term, low-dose ASA for secondary prevention provided that the PPI is available at OTC prices. At Rx prices, cotherapy is costeffective only in high-risk and elderly patients. These results were sensitive to the effectiveness of PPIs in reducing UGIB risk. Future studies are needed to better quantify the effectiveness of PPI cotherapy in reducing UGIB in average-risk patients as well as the impact of PPI cotherapy on ASA-related dyspepsia and compliance. 
